Arrowhead Pharmaceuticals (ARWR) Competitors $9.99 -0.26 (-2.54%) Closing price 04/8/2025 04:00 PM EasternExtended Trading$10.02 +0.03 (+0.31%) As of 04/8/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARWR vs. LNTH, BBIO, RVMD, LEGN, SRPT, TGTX, AXSM, TLX, BPMC, and KRYSShould you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include Lantheus (LNTH), BridgeBio Pharma (BBIO), Revolution Medicines (RVMD), Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), TG Therapeutics (TGTX), Axsome Therapeutics (AXSM), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Arrowhead Pharmaceuticals vs. Lantheus BridgeBio Pharma Revolution Medicines Legend Biotech Sarepta Therapeutics TG Therapeutics Axsome Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Krystal Biotech Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk. Which has preferable earnings and valuation, ARWR or LNTH? Lantheus has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArrowhead Pharmaceuticals$2.50M548.72-$599.49M-$5.17-1.93Lantheus$1.53B4.17$326.66M$4.3721.38 Do analysts rate ARWR or LNTH? Arrowhead Pharmaceuticals currently has a consensus price target of $41.44, indicating a potential upside of 314.86%. Lantheus has a consensus price target of $129.43, indicating a potential upside of 38.56%. Given Arrowhead Pharmaceuticals' higher possible upside, equities analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Lantheus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arrowhead Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60Lantheus 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in ARWR or LNTH? 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 1.5% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, ARWR or LNTH? Arrowhead Pharmaceuticals has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Does the MarketBeat Community believe in ARWR or LNTH? Arrowhead Pharmaceuticals received 207 more outperform votes than Lantheus when rated by MarketBeat users. However, 66.02% of users gave Lantheus an outperform vote while only 65.51% of users gave Arrowhead Pharmaceuticals an outperform vote. CompanyUnderperformOutperformArrowhead PharmaceuticalsOutperform Votes54965.51% Underperform Votes28934.49% LantheusOutperform Votes34266.02% Underperform Votes17633.98% Is ARWR or LNTH more profitable? Lantheus has a net margin of 28.57% compared to Arrowhead Pharmaceuticals' net margin of 0.00%. Lantheus' return on equity of 44.29% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Arrowhead PharmaceuticalsN/A -236.60% -64.09% Lantheus 28.57%44.29%23.52% Does the media refer more to ARWR or LNTH? In the previous week, Lantheus had 10 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 14 mentions for Lantheus and 4 mentions for Arrowhead Pharmaceuticals. Lantheus' average media sentiment score of 1.40 beat Arrowhead Pharmaceuticals' score of 0.63 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Lantheus 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryLantheus beats Arrowhead Pharmaceuticals on 13 of the 18 factors compared between the two stocks. Remove Ads Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARWR vs. The Competition Export to ExcelMetricArrowhead PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.37B$6.07B$5.08B$6.91BDividend YieldN/A2.87%5.00%4.20%P/E Ratio-1.936.5321.3117.06Price / Sales548.72185.42349.5885.97Price / CashN/A65.6738.1534.64Price / Book6.495.356.053.66Net Income-$599.49M$141.19M$3.19B$247.27M7 Day Performance-18.11%-10.64%-7.80%-8.86%1 Month Performance-41.13%-20.11%-6.79%-12.84%1 Year Performance-61.13%-22.14%0.32%-10.80% Arrowhead Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARWRArrowhead Pharmaceuticals3.0846 of 5 stars$9.99-2.5%$41.44+314.9%-61.1%$1.37B$2.50M-1.93400Gap DownLNTHLantheus4.28 of 5 stars$97.50+1.4%$129.43+32.7%+56.4%$6.71B$1.53B16.31700Positive NewsBBIOBridgeBio Pharma4.5098 of 5 stars$34.72-1.1%$52.64+51.6%+6.6%$6.60B$221.90M-12.17400RVMDRevolution Medicines3.4597 of 5 stars$35.35-5.4%$66.31+87.6%-2.4%$6.56B$742,000.00-9.82250Analyst ForecastNews CoveragePositive NewsGap UpLEGNLegend Biotech2.5756 of 5 stars$34.13-2.7%$79.00+131.5%-43.9%$6.23B$627.24M-35.681,070Analyst ForecastNews CoveragePositive NewsGap UpSRPTSarepta Therapeutics4.7372 of 5 stars$63.56-9.7%$164.05+158.1%-61.0%$6.18B$1.90B50.941,314Gap UpTGTXTG Therapeutics3.2243 of 5 stars$38.26-4.0%$40.67+6.3%+137.3%$6.01B$329.00M-382.86290News CoveragePositive NewsGap UpAXSMAxsome Therapeutics4.658 of 5 stars$116.86-1.4%$167.64+43.5%+35.3%$5.69B$385.69M-19.49380Analyst ForecastAnalyst RevisionNews CoverageGap UpTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.62-3.6%$22.00+32.4%N/A$5.60B$783.21M0.00N/AGap UpBPMCBlueprint Medicines2.5585 of 5 stars$87.42-1.5%$124.95+42.9%-13.5%$5.59B$508.82M-80.98640Analyst ForecastPositive NewsGap UpKRYSKrystal Biotech4.7491 of 5 stars$178.02-3.2%$220.00+23.6%-12.0%$5.13B$290.52M59.54210Analyst Revision Remove Ads Related Companies and Tools Related Companies Lantheus Alternatives BridgeBio Pharma Alternatives Revolution Medicines Alternatives Legend Biotech Alternatives Sarepta Therapeutics Alternatives TG Therapeutics Alternatives Axsome Therapeutics Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Blueprint Medicines Alternatives Krystal Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARWR) was last updated on 4/9/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARWR Stock Free ARWR Stock Alerts